UroGen Pharma (URGN) Annual Income Statement

Income Statement Summary

UroGen Pharma (URGN) annual income statement covering fiscal 2020 through 2025, as reported to the SEC.

UroGen Pharma reported revenue of $109.79M in fiscal 2025, up 21.4% from $90.4M in fiscal 2024.
Gross profit was $97.34M, up 19.4% from $81.52M. That is a gross margin of 88.7%.
Operating income was -$124.86M, a bigger loss than the $96.78M in fiscal 2024. Operating margin was -113.7%.
Net loss was $153.49M, a bigger loss than the $126.87M in fiscal 2024. Net margin was -139.8%.
Diluted earnings per share was -$3.19, a bigger loss than the $2.96 in fiscal 2024.
Cost of revenue took 11.3% of revenue, research and development expenses 61.1% and selling, general and administrative expenses 141.3%.

Revenue has grown 56.2% a year on average since fiscal 2020, from $11.8M to $109.79M, rising in every year shown.

An income statement shows what a company sold and what it cost to run the business, ending with the profit left over.

Figures in USD thousands, except per share data

						Dec'25	Dec'24	Dec'23	Dec'22	Dec'21	Dec'20
Revenue
109,788	90,398	82,713	64,357	48,042	11,799	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Revenue						109,788	90,398	82,713	64,357	48,042	11,799	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Cost of revenue
12,447	8,881	9,361	7,654	5,157	1,009	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Cost of revenue						12,447	8,881	9,361	7,654	5,157	1,009	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Gross profit
97,341	81,517	73,352	56,703	42,885	10,790	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Gross profit						97,341	81,517	73,352	56,703	42,885	10,790	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Operating expenses:
Research and development expenses
67,107	57,145	45,614	52,906	47,642	47,310	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Research and development expenses						67,107	57,145	45,614	52,906	47,642	47,310	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Selling, general and administrative expenses
155,097	121,154	93,274	82,838	87,535	90,219	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Selling, general and administrative expenses						155,097	121,154	93,274	82,838	87,535	90,219	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Operating income (loss)
-124,863	-96,782	-65,536	-79,041	-92,292	-126,739	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Operating income (loss)						-124,863	-96,782	-65,536	-79,041	-92,292	-126,739	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Financing on prepaid forward obligation
18,503	23,411	21,552	21,559	17,291	-	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Financing on prepaid forward obligation						18,503	23,411	21,552	21,559	17,291	-	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Interest expense on long-term debt
15,345	12,521	14,715	8,438	-	-	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Interest expense on long-term debt						15,345	12,521	14,715	8,438	-	-	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Interest and other income, net
5,295	8,672	3,479	1,010	-	1,629	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Interest and other income, net						5,295	8,672	3,479	1,010	-	1,629	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Interest and other income, net
-	-	-	-	212	-	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Interest and other income, net						-	-	-	-	212	-	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Loss before income taxes
-153,416	-124,042	-98,324	-108,028	-109,371	-125,110	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Loss before income taxes						-153,416	-124,042	-98,324	-108,028	-109,371	-125,110	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Income tax expense
78	2,832	3,920	1,755	1,449	3,374	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Income tax expense						78	2,832	3,920	1,755	1,449	3,374	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Net loss
-153,494	-126,874	-102,244	-109,783	-110,820	-128,484	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Net loss						-153,494	-126,874	-102,244	-109,783	-110,820	-128,484	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Statements of comprehensive loss
Net loss
-153,494	-126,874	-102,244	-109,783	-110,820	-128,484	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Net loss						-153,494	-126,874	-102,244	-109,783	-110,820	-128,484	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Other comprehensive loss
Unrealized loss on investments
-37	44	119	-82	-296	-5	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Unrealized loss on investments						-37	44	119	-82	-296	-5	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Comprehensive loss
-153,531	-126,830	-102,125	-109,865	-111,116	-128,489	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Comprehensive loss						-153,531	-126,830	-102,125	-109,865	-111,116	-128,489	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Net loss per ordinary share - basic and diluted (in dollars per share)
-3.19	-2.96	-3.55	-4.81	-4.96	-	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Net loss per ordinary share - basic and diluted (in dollars per share)						-3.19	-2.96	-3.55	-4.81	-4.96	-	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Weighted average number of shares outstanding used in computation of basic and diluted loss per ordinary share (in shares)
48,116	42,876	28,834	22,806	22,347	-	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Weighted average number of shares outstanding used in computation of basic and diluted loss per ordinary share (in shares)						48,116	42,876	28,834	22,806	22,347	-	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Loss per ordinary share basic and diluted (in dollars per share)
-	-	-	-	-	-5.90	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Loss per ordinary share basic and diluted (in dollars per share)						-	-	-	-	-	-5.90	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Weighted average number of shares outstanding used in computation of basic and diluted loss per ordinary share (in shares)
-	-	-	-	-	21,780	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx
Weighted average number of shares outstanding used in computation of basic and diluted loss per ordinary share (in shares)						-	-	-	-	-	21,780	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx	xxxxx